Radiation therapy for canine appendicular osteosarcoma

Coomer, Alastair R.; Farese, James P.; Milner, Rowan J.; Liptak, Julius M.; Bacon, Nicholas J.; Lurie, D. M.

doi:10.1111/j.1476-5829.2008.00177.x

Cited by 57 publications

(61 citation statements)

References 48 publications

(143 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternative treatments to suppress tumor growth and alleviate the pain of the primary tumor would have significant clinical relevance in these cases. Coarsely fractionated, or 'palliative' radiation therapy using several fractioned doses (for example, 8-10 Gy per fraction) may be used for palliation of pain, but is not able to achieve local tumor control (3)(4)(5). High dose per fraction radiation therapy has been described as a method for local tumor control using stereotactic radiosurgery, particularly when combined with chemotherapy (5,6).…”

Section: Introductionmentioning

confidence: 99%

“…Coarsely fractionated, or 'palliative' radiation therapy using several fractioned doses (for example, 8-10 Gy per fraction) may be used for palliation of pain, but is not able to achieve local tumor control (3)(4)(5). High dose per fraction radiation therapy has been described as a method for local tumor control using stereotactic radiosurgery, particularly when combined with chemotherapy (5,6). Stereotactic radiosurgery is able to deliver a single very high dose of radiation (for example, 30 Gy) using multiple beams with a linear accelerator to a designated target, while sparing the surrounding tissues (6).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Relative biological effectiveness in canine osteosarcoma cells irradiated with accelerated charged particles

et al. 2016

View full text Add to dashboard Cite

Abstract. Heavy ions, characterized by high linear energy transfer (LET) radiation, have advantages compared with low LET protons and photons in their biological effects. The application of heavy ions within veterinary clinics requires additional background information to determine heavy ion efficacy. In the present study, comparison of the cell-killing effects of photons, protons and heavy ions was investigated in canine osteosarcoma (OSA) cells in vitro. A total of four canine OSA cell lines with various radiosensitivities were irradiated with 137 Cs gamma-rays, monoenergetic proton beams, 50 keV/µm carbon ion spread out Bragg peak beams and 200 keV/µm iron ion monoenergetic beams. Clonogenic survival was examined using colony-forming as says, and relative biological effectiveness (RBE) values were calculated relative to gamma-rays using the D 10 value, which is determined as the dose (Gy) resulting in 10% survival. For proton irradiation, the RBE values for all four cell lines were 1.0-1.1. For all four cell lines, exposure to carbon ions yielded a decreased cell survival compared with gamma-rays, with the RBE values ranging from 1.56-2.10. Iron ions yielded the lowest cell survival among tested radiation types, with RBE values ranging from 3.51-3.69 observed in the three radioresistant cell lines. The radiosensitive cell line investigated demonstrated similar cell survival for carbon and iron ion irradiation. The results of the present study suggest that heavy ions are more effective for killing radioresistant canine OSA cells when compared with gamma-rays and protons. This markedly increased efficiency of cell killing is an attractive reason for utilizing heavy ions for radioresistant canine OSA.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Relative biological effectiveness in canine osteosarcoma cells irradiated with accelerated charged particles

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In the described series there were no cases of local recurrence or new metastatic lesions. However, the purpose of this report was not to describe the efficacy of ECIR, which has been widely demonstrated in both human studies311–1422–25 and animal models192026 but rather to document the application of the technique in conjunction with extendable distal femoral endoprosthesis in the skeletally immature. One disadvantage of this technique is that the irradiated and reimplanted segment of bone cannot be fully assessed histologically.…”

Section: Discussionmentioning

confidence: 99%

Use of irradiated autologous bone in joint sparing endoprosthetic femoral replacement tumor surgery

Vijayan

Bartlett

Lee

et al. 2011

IJOO

View full text Add to dashboard Cite

Background:Joint preservation is usually attempted in cases of bone tumors, though insufficient bone following tumour resection may prevent fixation of conventional joint sparing prosthesis. To preserve the hip joint in skeletally immature patients, we have combined autologous proximal femoral irradiation and intercalary re-implantation with custom made distal femoral replacements.Materials and Methods:A retrospective cohort study of four patients (aged 4-12 years); in whom irradiated autologous bone was combined with an extendable distal femoral endoprostheses was performed. There were three cases of osteosarcoma and one case of Ewing’s sarcoma.Results:At a mean follow-up of 70.5 months (range 26-185 months), all four patients were alive without evidence of local recurrence. There was no evidence of metastatic disease in three patients while one patient showed chest metastatic disease at presentation. In all cases, the irradiated segment of bone united with the proximal femur and demonstrated bone ongrowth at the prosthetic collar. There were no cases of loosening or peri-prosthetic fracture. One implant was revised after 14 years following fracture of the extending component of the endoprosthesis.Conclusions:We report encouraging results utilizing irradiated autologous proximal femoral bone combined with distal femoral replacement in skeletally immature patients.

show abstract

“…Stereotactic radiation therapy has been reported as an alternative means to achieve local control [10, 11]. The survival time of canine appendicular OSA with adequate local control and without adjuvant chemotherapy is 119–175 days with a 12 month survival rate of only 11–21% [12].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of P16 expression in canine appendicular osteosarcoma

et al. 2017

View full text Add to dashboard Cite

BackgroundOsteosarcoma (OSA) is a common malignant bone tumor of large breed dogs that occurs at predictable anatomic sites. At the time of initial diagnosis, most affected dogs have occult pulmonary metastases. Even with aggressive surgical treatment combined with chemotherapy, the majority of dogs diagnosed with OSA live less than 1 year from the time of diagnosis. The ability to identify canine OSA cases most responsive to treatment is needed. In humans, OSA is also an aggressive tumor that is histologically and molecularly similar to canine OSA. The expression of the tumor suppressor gene product P16 by human OSA tissue has been linked to a favorable response to chemotherapy.ResultsWe identified an antibody that binds canine P16 and developed a canine OSA tissue microarray in order to test the hypothesis that P16 expression by canine OSA tissue is predictive of clinical outcome following amputation and chemotherapy. Although statistical significance was not reached, a trend was identified between the lack of canine OSA P16 expression and a shorter disease free interval.ConclusionsThe identification of a molecular marker for canine OSA is an important goal and the results reported here justify a larger study.

show abstract

Radiation therapy for canine appendicular osteosarcoma

Cited by 57 publications

References 48 publications

Relative biological effectiveness in canine osteosarcoma cells irradiated with accelerated charged particles

Relative biological effectiveness in canine osteosarcoma cells irradiated with accelerated charged particles

Use of irradiated autologous bone in joint sparing endoprosthetic femoral replacement tumor surgery

Evaluation of P16 expression in canine appendicular osteosarcoma

Contact Info

Product

Resources

About